BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30358515)

  • 21. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
    Wu MH; Shen WT; Gosnell J; Duh QY
    Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modification of the Tumor-Node-Metastasis Staging System for Differentiated Thyroid Carcinoma by Considering Extra-Thyroidal Extension and Lateral Cervical Lymph Node Metastasis.
    Kim M; Kim WG; Jeon MJ; Kim HK; Yi HS; Kim ES; Kim BH; Kim WB; Shong YK; Kang HC; Kim TY
    Endocrinol Metab (Seoul); 2020 Mar; 35(1):149-156. PubMed ID: 32207275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TUMOR SIZE IS AN INDEPENDENT PREDICTOR OF MORTALITY RISK IN DIFFERENTIATED THYROID CANCER PATIENTS WITH T4 DISEASE.
    Wang Z; Zhang Q; Ye H; Jia C; Lv Z; Liu J; Yin Z
    Endocr Pract; 2020 May; 26(5):499-507. PubMed ID: 31968190
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer.
    Tam S; Amit M; Boonsripitayanon M; Busaidy NL; Cabanillas ME; Waguespack SG; Gross ND; Grubbs EG; Williams MD; Lai SY; Sturgis EM; Zafereo ME
    Thyroid; 2018 Aug; 28(8):982-990. PubMed ID: 29936892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Significance of Tumor Size in Gross Extrathyroidal Extension to Strap Muscles (T3b) in Papillary Thyroid Carcinoma: Comparison with T2.
    Park J; Kang IK; Bae JS; Kim JS; Kim K
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study.
    Kim M; Kim HI; Jeon MJ; Kim HK; Kim EH; Yi HS; Kim ES; Kim H; Kim BH; Kim TY; Kim SW; Kang HC; Kim WB; Chung JH; Shong YK; Kim TH; Kim WG
    Oral Oncol; 2018 Dec; 87():97-103. PubMed ID: 30527251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updated guidelines on the preoperative staging of thyroid cancer.
    Kim HJ
    Ultrasonography; 2017 Oct; 36(4):292-299. PubMed ID: 28607324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is There a Difference Between Minimal and Gross Extension into the Strap Muscles for the Risk of Recurrence in Papillary Thyroid Carcinomas?
    Danilovic DLS; Castroneves LA; Suemoto CK; Elias LO; Soares IC; Camargo RY; Correa FA; Hoff AO; Marui S
    Thyroid; 2020 Jul; 30(7):1008-1016. PubMed ID: 32059626
    [No Abstract]   [Full Text] [Related]  

  • 29. A relook at the 8th edition of the AJCC TNM staging system of anaplastic thyroid carcinoma: A SEER-based study.
    Xiang J; Wang Z; Sun W; Zhang H
    Clin Endocrinol (Oxf); 2021 Apr; 94(4):700-710. PubMed ID: 33368530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts.
    Pontius LN; Oyekunle TO; Thomas SM; Stang MT; Scheri RP; Roman SA; Sosa JA
    Thyroid; 2017 Nov; 27(11):1408-1416. PubMed ID: 28891405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
    Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
    Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer.
    Bortz MD; Kuchta K; Winchester DJ; Prinz RA; Moo-Young TA
    Surgery; 2021 Jan; 169(1):2-6. PubMed ID: 32682508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?
    Ebina A; Sugitani I; Fujimoto Y; Yamada K
    Surgery; 2014 Dec; 156(6):1579-88; discussion 1588-9. PubMed ID: 25262223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma.
    Xu S; Sagiv O; Rubin ML; Sa HS; Tetzlaff MT; Nagarajan P; Ning J; Esmaeli B
    JAMA Ophthalmol; 2019 May; 137(5):537-542. PubMed ID: 30869769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal extrathyroidal extension does not affect survival of well-differentiated thyroid cancer.
    Al-Qurayshi Z; Shama MA; Randolph GW; Kandil E
    Endocr Relat Cancer; 2017 May; 24(5):221-226. PubMed ID: 28249964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does macroscopic extrathyroidal extension to the strap muscles alone affect survival in papillary thyroid carcinoma?
    Harries V; McGill M; Yuan A; Wang LY; Tuttle RM; Shaha AR; Shah JP; Wong RJ; Patel SG; Ganly I
    Surgery; 2022 May; 171(5):1341-1347. PubMed ID: 34600743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging.
    Turk AT; Asa SL; Baloch ZW; Faquin WC; Fellegara G; Ghossein RA; Giordano TJ; LiVolsi VA; Lloyd R; Mete O; Rosai J; Suster S; Thompson LDR; Wenig BM
    Thyroid; 2019 May; 29(5):619-624. PubMed ID: 30913992
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years?
    Kim M; Kim YN; Kim WG; Park S; Kwon H; Jeon MJ; Ahn HS; Jung SH; Kim SW; Kim WB; Chung JH; Shong YK; Kim TH; Kim TY
    Clin Endocrinol (Oxf); 2017 Mar; 86(3):438-443. PubMed ID: 27731521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma.
    Kim TH; Kim YN; Kim HI; Park SY; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Kim K; Jeong JG; Kim SW; Chung JH
    Oral Oncol; 2017 Aug; 71():81-86. PubMed ID: 28688696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
    Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
    Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.